Loading
Latest filing published 22 Apr 2021 for GenMark Diagnostics, Inc., €2.7M.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Michael Kagnoff appears in our data through filings on GenMark Diagnostics, Inc. shares, published by SEC (Form 4). In total, 14 filings cover trades dated from 10 March 2016 to 22 April 2021.
Purchases make up the whole of the open-market record (7 purchases, €223k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 6 share grants.
In size, the median ticket on the buying side is €23k. Across 7 purchases, this insider has always bought alone, with no colleague buying within 30 days.
The latest filing, published on 22 April 2021, reports a transaction of €2.7M in GenMark Diagnostics, Inc. The clock since the last published purchase (5 March 2020) now reads 2,423 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations